title: Etirinotecan pegol: an option for late-stage breast cancer?
authors.affiliation: Department of Oncology, Herlev University Hospital, DK-2730 Herlev, Copenhagen, Denmark. Electronic address: nielsen.01@regionh.dk.
authors.forename: Dorte L
authors.initials: DL
authors.lastname: Nielsen
authors.forename: Nils
authors.initials: N
authors.lastname: Brünner
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006576:Heterocyclic Compounds, 4 or More Rings / Q000008:administration & dosage*; D006801:Humans; D000077146:Irinotecan; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D059004:Topoisomerase I Inhibitors / Q000008:administration & dosage*
chemical_list: D006576:Heterocyclic Compounds, 4 or More Rings; D059004:Topoisomerase I Inhibitors; D011092:Polyethylene Glycols; D000077146:Irinotecan; C581703:etirinotecan pegol; D002166:Camptothecin